Microvascular and Antiinflammatory Effects of Rivaroxaban Compared to Low Dose Aspirin in Typ-2 Diabetic Patients With Cardiovascular Disease and Subclinical Inflammation
Phase of Trial: Phase III
Latest Information Update: 05 Oct 2016
At a glance
- Drugs Rivaroxaban (Primary) ; Aspirin
- Indications Cardiovascular disorders
- Focus Therapeutic Use
- Acronyms MicroVasc-DIVA
- 10 Jun 2017 Biomarkers information updated
- 29 Sep 2016 Planned End Date changed from 1 Dec 2017 to 1 Jul 2019.
- 29 Sep 2016 Planned primary completion date changed from 1 Dec 2016 to 1 Dec 2018.